Ospemifene efficacy and safety data in women with vulvovaginal atrophy

References

• Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric. 2014;17(5):557–563.
   PubMed Web of Science ®Google Scholar
• Sánchez-Borrego R, Manubens M, Navarro MC, et al. Position of the Spanish Menopause Society regarding vaginal health care in postmenopausal women. Maturitas. 2014;78(2):146–150.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090–3096.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–238.
   PubMed Web of Science ®Google Scholar
• Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–711.
   PubMed Web of Science ®Google Scholar
• Freedman MA. Vaginal pH, estrogen and genital atrophy | menopause management. Menopause Manag. 2008;9–13.
   Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric J Int Menopause Soc. 2014;17(1):3–9.
   PubMed Web of Science ®Google Scholar
• Palma F, Della Vecchia E, Cagnacci A. Medical and patient attitude towards vaginal atrophy: the AGATA study. Climacteric J Int Menopause Soc. 2016;19(6):553–557.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Xholli A, Sclauzero M, et al. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019;22(1):85–89.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric. 2012;15(1):36–44.
   PubMed Web of Science ®Google Scholar
• Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. IJWH. 2018;10:387–395.
   PubMed Web of Science ®Google Scholar
• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24:728.
   PubMed Web of Science ®Google Scholar
• Shin JJ, Kim SK, Lee JR, et al. Ospemifene: a novel option for the treatment of vulvovaginal atrophy. J Menopausal Med. 2017;23(2):79.
   PubMedGoogle Scholar
• McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010;6(6):773–779.
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Uusitalo J, Lehtinen T, et al. Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. IJMS. 2013;14(7):14064–14075.
   Google Scholar
• Yadlapalli SSR, Katari NK, Manabolu Surya SB. Determination of ospemifene in human plasma by LC‐MS/MS and its application to a human pharmacokinetic study. Biomed Chromatogr. 2018;33:e4451.
   Google Scholar
• Kao C-J, Wurz GT, Lin Y-C, et al. Repurposing ospemifene for potentiating an antigen-specific immune response. Menopause. 2017;24(4):437–451.
   PubMed Web of Science ®Google Scholar
• Bondi C, Ferrero S, Scala C, et al. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. Expert Opin Drug Metab Toxicol. 2016;12(10):1233–1246.
   PubMed Web of Science ®Google Scholar
• Kubota R, Matsumoto S, Wajima T. Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors. Int J Clin Pharmacol Ther . 2017;55(04):339–347.
   PubMedGoogle Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17:480–486.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623–630.
   PubMed Web of Science ®Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health. 2018;27(1):14–23.
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA approved drug products: OSPHENA® (ospemifene) 60 mg tablet [Internet]. [cited 2019. Nov 21]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203505.
   Google Scholar
• Preston RA, Marbury TC, Wajima T, et al. The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist. Am J Ther. 2015;22(3):171–181.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Senshio: EPAR – Product Information. Last updated Nov 2019 [Internet]. European Medicine Agency. 2018. [cited 2019 Nov 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/senshio.
   Google Scholar
• Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause. 2015;22(1):36–43.
   PubMed Web of Science ®Google Scholar
• Archer DF, Altomare C, Jiang W, et al. Ospemifeneʼs effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause. 2017;24(10):1167–1174.
   PubMed Web of Science ®Google Scholar
• Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol off J Int Soc Gynecol Endocrinol. 2004;18(3):152–158.
   PubMed Web of Science ®Google Scholar
• Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013;78(12–13):1273–1280.
   PubMed Web of Science ®Google Scholar
• Soe L, Wurz G, Kao C-J, et al. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health. 2013;5:605–611.
   PubMedGoogle Scholar
• Eigeliene N, Kangas L, Hellmer C, et al. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016;23:719–730.
   PubMed Web of Science ®Google Scholar
• Palacios S, Cancelo MJ. Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. IJWH. 2016; 8:617–626.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Martelli V, et al. Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol Endocrinol. 2017;33(12):946–950.
   PubMed Web of Science ®Google Scholar
• Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Murina F, Perrone G, et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol [Internet]. 2017. [cited 2019 Jun 25]; Available from: http://www.minervamedica.it/index2.php?show=R09Y2017N04A0370
   Google Scholar
• Goldstein I, Simon JA, Kaunitz AM, et al. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices. Menopause. 2019.
   Web of Science ®Google Scholar
• Palacios S, Panay N, Sánchez-Borrego R, et al. Earlier treatment of vulvovaginal atrophy in post-menopausal women may improve treatment outcomes. J Gynecol Womens Health. 2019;16(1):555928.
   Google Scholar
• Murina F, Di Francesco S, Oneda S. Vulvar vestibular effects of ospemifene: a pilot study. Gynecol Endocrinol. 2018;34(7):631–635.
   PubMed Web of Science ®Google Scholar
• Goldstein SW, Winter AG, Goldstein I. Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study. Sex Med. 2018;6(2):154–161.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Gava G, et al. Structure of epithelial and stromal compartments of vulvar and vaginal tissue from women with vulvo-vaginal atrophy taking ospemifene. J Sex Med. 2018;15(12):1776–1784.
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–232.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Sciuga V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–669.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Di Pinto A, Sciuga V, et al. Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. Gynecol Endocrinol. 2018;34(2):140–143.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol. 2017;33(12):942–945.
   PubMed Web of Science ®Google Scholar
• Bruyniks N, Biglia N, Palacios S, et al. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017;20(3):195–204.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019;121:86–92.
   PubMed Web of Science ®Google Scholar
• Lee A, Kim TH, Lee HH, et al. Therapeutic approaches to atrophic vaginitis in postmenopausal women: a systematic review with a network meta-analysis of randomized controlled trials. J Menopausal Med. 2018;24(1):1.
   PubMedGoogle Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). [Internet]. European Medicines Agency; 2014 [Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002780/WC500182777.pdf
   Google Scholar
• Constantine GD, Archer DF, Pollycove R, et al. Ospemifeneʼs effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. Menopause. 2016;23(9):957–964.
   PubMed Web of Science ®Google Scholar
• Bruyniks N, Pup LD, Biglia N. Safety and efficacy of ospemifene in women with a history of breast cancer. J Gynecol Women’s Health. 2019;13(5):555871.
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation) [Internet]. European Medicines Agency; 2014 [Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002780/WC500177633.pdf.
   Google Scholar
• Berga SL. Profile of ospemifene in the breast. Reprod Sci. 2013;20(10):1130–1136.
   PubMed Web of Science ®Google Scholar
• Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141(2):809–820.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety. Maturitas. 2019;121:93–100.
   PubMed Web of Science ®Google Scholar
• Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24(4):314–318.
   PubMed Web of Science ®Google Scholar
• De Rosa N, Lavitola G, Giampaolino P, et al. Impact of ospemifene on quality of life and sexual function in young survivors of cervical cancer: a prospective study. BioMed Res Int. 2017;2017:1–8.
   Web of Science ®Google Scholar
• Del Pup L, Villa P, Amar ID, et al. Approach to sexual dysfunction in women with cancer. Int J Gynecol Cancer. 2019;29(3):630–634.
   PubMed Web of Science ®Google Scholar
• Bruyniks N. Safety of ospemifene during real-life use. J Gynecol Womens Health [Internet]. 2018;9(3):555762; [cited 2019 Jun 25]. Available from: https://juniperpublishers.com/jgwh/JGWH.MS.ID.555762.php
   Google Scholar